10x Genomics Selects First 45 Members for Visium Clinical Translational Research Network
“The technologies powering today’s research have led to discoveries that would have been unprecedented ten years ago, but the tools that help translate genomic research to a clinical setting haven’t always kept pace,” said
The first 45 members of 10x Genomics’ Visium CTRN were selected from 185 total applications and represent a diverse range of studies that are taking place around the world. The 10x Genomics CTRN will connect researchers across 39 global institutions, including:
- Barcelona Supercomputing Center
Cancer Research Centre of Lyon(CRCL)
- Centre de Recherche des Cordeliers (
Inserm, Sorbonne Université, Université de Paris) Duke University Garvan Institute of Medical Research
Italiano Buenos Aires, IMTIB Humanitas Research Hospital
- Institut Imagine
- Johns Hopkins Medical Institutions
Josep Carreras Leukaemia Research Institute Lieber Institute for Brain Development
- Ludwig-Maximilians University Munich
Mass General Cancer Center Nanjing Drum Tower Hospital Queensland University of Technology RIKEN Center for Biosystems Dynamics Research RIKEN Center for Integrative Medical Sciences Sylvester Comprehensive Cancer Centerand Bascom Palmer Eye Institute, University of Miami Miller School of Medicine University of Michigan Rogel Cancer Center
“We are excited to be a part of the collaborative Visium Clinical Translational Research Network and look forward to harnessing the power of spatial gene expression,” said Dr.
As members of the Visium CTRN, researchers gain exclusive access to a collaborative, global research community dedicated to accelerating clinical translational research workflows, as well as substantial discounts and specialized support relating to the 10x Genomics Visium platform. Members will also have the opportunity to present at the 10x Genomics CTRN Spatial Summit, the details of which are expected to be revealed later this year.
“Membership in the 10x Genomics CTRN is an important step forward for my lab, enabling us to pursue the translation of cellular genomic discoveries into meaningful improvements for cancer patients,” said Dr.
“We’re really excited to participate in the CTRN, and use Visium to better characterize spatial patterns of genes dysregulated in debilitating brain disorders,” added Dr.
More information on the Visium Clinical Translational Research Network and its members can be found by visiting www.10xgenomics.com/ctrn.
To learn more about
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology. These forward-looking statements include statements regarding
Source: 10x Genomics, Inc.